January 2026 Research Update

Across these papers, aortic dissection in younger people was linked to inherited conditions and sometimes occurred without a very enlarged aorta, which can complicate risk prediction. In Marfan syndrome specifically, endovascular approaches for type B dissection often improved blood flow quickly, but long-term durability was uncertain and some patients needed additional procedures. [1] [2] [3]

In a long-running regional registry of sudden deaths in people age 40 or younger, thoracic aortic dissection accounted for 28 of 941 sudden deaths, and about half of the tested cases had a disease-causing or likely disease-causing genetic variant. Many type A dissections had an aortic diameter below 50 mm at autopsy, and symptoms such as chest or back pain were reported in under half of cases, meaning some events were not preceded by clear warning signs. [1]

In a small 7-patient case series of Marfan syndrome with type B aortic dissection treated with thoracic endovascular aortic repair (TEVAR), imaging showed rapid true-lumen expansion and stabilization, which also helped some patients proceed through staged or hybrid repairs. However, several patients had procedure-related issues such as endoleaks or bleeding, and some later required repeat TEVAR or open repair, highlighting uncertainty about long-term durability in this group. [2]

Two individual Marfan cases described a specific reason TEVAR can be complicated: a patent ductus arteriosus (PDA) can feed ongoing blood flow into the false channel and lead to a type 2 endoleak. In both patients, closing the PDA (and in one case adding other endovascular steps) was followed by follow-up imaging showing the endoleak resolved. [3]

For patients and caregivers, these studies mainly add context for why dissection risk and outcomes can vary in Marfan syndrome and other inherited aortic conditions. The registry data suggests that some severe events in young people can happen even when the aorta is not extremely enlarged and that inherited gene changes are often involved, but it does not show how to predict risk for an individual. The TEVAR reports are early, small-scale clinical experience: they describe how blood flow and symptoms can improve quickly after the procedure, but they also show that follow-up outcomes can include repeat procedures, and rare anatomy (like a PDA) may affect results; larger studies are still needed to know how often these situations occur and what long-term outcomes look like. [1] [2] [3]

Across these studies, pregnancy in Marfan syndrome was linked to a higher chance of dangerous aorta problems and higher maternal death risk than pregnancies without Marfan syndrome, and newborns also had more complications. When a severe aorta emergency (type A aortic dissection) occurred, outcomes differed depending on how far along the pregnancy was and how delivery and heart surgery were timed. [4] [5]

In a nationwide Taiwan registry including 794 pregnancies in 500 women with Marfan syndrome, severe aortic complications happened more often than in pregnancies without Marfan syndrome (1.1% vs 0.0005%). Short-term maternal death within 42 days was also higher (0.1% vs 0.02%), and longer-term risks stayed elevated over an average 10.7 years of follow-up. [4]

The same registry study reported that babies born to mothers with Marfan syndrome tended to be born earlier and with lower birth weight, and they more often had complications needing neonatal intensive care. This suggests the pregnancy can affect both maternal heart safety and early newborn health. [4]

In a 25-year retrospective series of 60 people with type A aortic dissection during pregnancy or postpartum (39 with Marfan syndrome), most were treated with surgery, but maternal and fetal deaths still occurred and varied by treatment strategy. Ten-year survival was 79.3% for mothers and 67.7% for fetuses, and some patients later needed additional aorta operations (10 reoperations in 8 patients, mostly in Marfan syndrome). The authors described different approaches based on gestational age, including delivery-first and a single-stage delivery plus aorta repair later in pregnancy. [5]

For patients and caregivers, these results mainly clarify the level and types of risk that have been observed when Marfan syndrome and pregnancy overlap: rare but serious aorta emergencies, higher maternal death risk, and more newborn complications than in pregnancies without Marfan syndrome. The registry data provides broader, population-level context, while the aortic dissection series focuses on outcomes once an emergency occurs and shows that results can differ depending on pregnancy stage and how delivery and surgery are coordinated. What remains uncertain is how much individual risk varies based on personal factors that are not detailed here, and which specific care pathways lead to the best outcomes across different settings. [4] [5]

Across these papers, researchers focused on why the aorta weakens and enlarges in Marfan syndrome and why symptoms can vary between people. One study (mainly in mice and lab-grown human cells) pointed to a specific chain of signals inside aortic muscle cells that may increase cell stiffness and speed aneurysm changes. A separate small human genetic study suggested that the exact type of FBN1 gene variant alone may not explain how the condition looks in every patient, hinting that other genetic factors may also play a role. [6] [7]

In Marfan syndrome mice and in human Marfan aorta samples, fibroblast growth factor 12 (FGF12) was higher in aortic smooth muscle cells, and it increased further with growth-factor signaling and with mechanical stretch. In lab experiments, higher FGF12 boosted angiotensin signaling inside the cells and activated pathways linked to RhoA/ROCK-driven cytoskeletal remodeling, leading to stiffer cells. In mice, having only one working copy of Fgf12 reduced thoracic aortic aneurysm progression and reduced measures of arterial stiffening compared with typical Marfan-model mice. [6]

In a small retrospective cohort of 12 Sri Lankan patients with FBN1-related type-1 fibrillinopathies (including Marfan syndrome, MASS syndrome, and ectopia lentis syndrome), researchers reported four previously unreported FBN1 variants. They did not see a strong overall link between specific variant types and overall clinical severity, including that variants in a region sometimes linked to very severe early disease did not consistently cause severe disease in this group. Some variant types (frameshift and splice-site) were noted alongside more pronounced skeletal and facial features in this cohort. [7]

For patients and caregivers, these studies mainly add background about why aortic disease can progress and why Marfan features can differ between families and populations. The FGF12 work is not a clinical treatment study; it is preclinical research that helps map out possible biological targets involved in aortic wall stiffness and aneurysm changes, and it remains uncertain how directly these results translate to people. The genetic study suggests that even when Marfan syndrome is caused by changes in FBN1, the exact variant may not fully predict what a person experiences, which supports ongoing research into additional genetic modifiers. [6] [7]

Across two retrospective studies in Marfan syndrome with ectopia lentis (a displaced natural lens), different ways of fixing an artificial lens inside the eye generally led to better vision and acceptable lens positioning over about 1 year to nearly 2 years of follow-up. However, neither approach was free of issues: some eyes had the lens sit slightly off-center, and a small number developed complications that could require extra monitoring or additional procedures. [8] [9]

In a pediatric cohort comparing two techniques, both the modified Yamane intrascleral fixation and capsular bag fixation using a Cionni ring improved corrected vision, and about three-quarters of eyes in each group ended with vision better than 20/40. Lens tilt measurements were similar between groups, and lens decentration occurred in both. [8]

In that same comparison, more varied postoperative problems were reported in the modified Yamane group, including retina problems (such as retinal tear or detachment), glaucoma, and swelling in the central retina, and a few eyes needed additional surgery related to the lens support. Cell loss in the clear front window of the eye (the cornea) occurred in both groups without a clear difference between them. [8]

A separate multicenter case series looked at a sutureless intrascleral fixation technique after lens removal and found improved corrected distance vision at 12 months, minimal average lens tilt, and no lens dislocations during follow-up. Corneal cell counts decreased on average, and complications included one case of macular swelling that later developed an epiretinal membrane and one case of lens-support exposure. [9]

For patients and caregivers, these studies add to the evidence that more than one surgical approach can improve vision after ectopia lentis in Marfan syndrome, including options designed to avoid stitches. What remains uncertain is how these choices compare over the long term, because the studies were small, retrospective, and followed patients for about 12 to 23 months, while some important issues (lens stability, retina risks, glaucoma, and surface exposure of lens supports) may appear later. [8] [9]

Across these studies, pain in Marfan syndrome was described as having multiple parts: day-to-day symptoms that may shift with coping skills, differences in how people move during common tasks, and possible changes in the nervous system that could help explain ongoing sensitivity. The overall picture suggests pain is not only about joints or tissues, but may also involve how the brain and spinal cord process pain signals. However, the clinical evidence is still early, with one non-randomized program study and separate biomechanics and animal-model research. [10] [11] [12]

In a single-arm U.S. cohort of 92 adults with self-reported Marfan syndrome or related connective-tissue conditions and chronic pain, a 2-hour online Empowered Relief class met feasibility targets and was followed by improvements in several outcomes by 3 months. Pain interference decreased by 5.7 points (meeting the study-defined meaningful change threshold), while pain intensity decreased by 1.3 points (not reaching the study-defined meaningful change threshold). Participants also reported reductions in sleep disturbance, pain catastrophizing, anxiety, anger, and depression. [10]

In a small cross-sectional biomechanics study (16 adults with Marfan syndrome and 16 matched controls), people with Marfan syndrome completed a sit-to-stand task more slowly and relied more on the ankle compared with controls. They showed higher ankle plantar-flexor moments and a higher total support moment, with a larger ankle contribution to overall support, even though some peak hip and knee measures and ground force patterns were similar between groups. This suggests that everyday movements may be performed with different joint-loading strategies in Marfan syndrome, although pain during the task was not measured. [11]

In a Marfan mouse model study, mice developed increasing sensitivity to mechanical and cold stimuli with age, and females showed earlier heat sensitivity changes, alongside worsening grip strength. The study also reported age- and sex-related gene-expression changes in the brain and spinal cord, including increased markers linked to excitatory signaling and pain sensitivity (such as certain glutamate receptor subunits and TRPV1) in older mice. These results support the idea that nervous-system changes could contribute to pain in this model, but animal findings may not translate directly to people. [12]

For patients and caregivers, this set of papers mainly adds context rather than changing care. The online single-session pain skills class study suggests a brief, remote approach can be delivered to adults with Marfan-related conditions and may relate to less disruption from pain and better sleep and emotional symptoms over the next few months, but it was not a randomized trial and diagnoses were self-reported. The movement study may help explain why some daily tasks feel tiring or awkward by showing different joint strategies during standing up, though it did not measure pain during the task. The mouse study is background research that may help scientists understand why pain sensitivity can persist or progress, including possible brain and spinal cord involvement; what remains uncertain is how these biological findings map to human symptoms and which factors best predict who experiences more pain.

Across these reports, surgery in people with Marfan syndrome (or suspected Marfan syndrome) was often manageable during the operation itself, but some complications showed up after surgery, especially involving breathing and the lungs. Because these are case reports, they show what can happen in individual patients rather than giving a clear estimate of how common these issues are. Overall, the direction of evidence is that planning for the airway, breathing support, and close monitoring after surgery can matter as much as the operation itself. [13] [14] [15]

In one adult man having open ventral hernia repair, the anesthesia course was largely stable, with successful airway management and no major heart rhythm or low-blood-flow events reported during surgery. Afterward, he developed a right-sided fluid collection in the chest (hydrothorax) and pneumonia, which were treated without additional procedures, and a brief episode of shortness of breath improved after pressure from an abdominal binder was reduced. [13]

In one woman after a Bentall procedure (a type of aortic root surgery), breathing problems after extubation led to respiratory failure requiring reintubation, and a bronchoscopy showed diffuse bronchomalacia (airway wall collapse). She improved with non-invasive ventilation and respiratory physiotherapy, went home after 35 days, and was reported to be stable at 6 months without rehospitalization, although she still needed non-invasive ventilation. [14]

A separate report focused on complex spine surgery in a woman with Marfan syndrome and severe spinal curvature, where robotic-navigation-assisted planning was used to place screws despite challenging bone anatomy. No surgical complications were reported, and follow-up imaging showed fusion with stable implants along with reduced pain and improved function, suggesting that careful surgical planning can help address anatomy-related challenges. [15]

For patients and caregivers, these reports mainly serve as background about the range of issues that can occur around major and non-cardiac surgeries in Marfan syndrome: some patients may have smooth operations, while others can develop significant breathing complications during recovery that require supportive care. Because the evidence here comes from three individual cases, it cannot tell how likely these complications are or which patients are most at risk, and larger studies would be needed to answer those questions.

Across these papers, researchers looked beyond the heart and blood vessels to other body systems that may be affected in Marfan syndrome. The overall picture is mixed in strength: one detailed mouse study connects Fbn1-related tissue changes to tear gland problems, while a small family report raises questions about neurodevelopment, and a database analysis discusses how genetic results can relate to medication labeling and pharmacogenetics. [16] [17] [18]

In a Marfan mouse model, reduced tear production occurred along with surface damage on the cornea (the clear front window of the eye), suggesting a dry-eye like problem can be part of Fbn1-related disease biology. The lacrimal (tear) glands also showed inflammation, scarring, and loss of normal elastic fibers, alongside higher activity in pathways involved in tissue remodeling and inflammation. [16]

A family-based genetic study reported that two rare FBN1 missense variants inherited together (compound heterozygous) tracked with more severe intellectual disability and behavior differences (including aggressive behavior and hyperactivity), while carrying only one of the variants appeared milder in that family. Because this is a single family, it cannot show how often this happens or whether it applies broadly to Marfan syndrome. [17]

A separate paper did not study Marfan syndrome specifically, but reviewed how certain gene findings (from a widely used list of secondary findings genes) can have medication-related implications across databases and drug labels. The authors found that different sources did not consistently flag the same gene-medication issues, suggesting that medication context tied to genetic results can be missed depending on which resource is consulted. [18]

For patients and caregivers, this set of studies mainly adds background about possible non-cardiovascular effects and how researchers are trying to connect gene changes to day-to-day symptoms. The mouse work supports the idea that tear gland and eye-surface symptoms could have a biological link to Fbn1 changes, but it is not proof of the same process in people. The family report suggests that, at least in rare situations, particular combinations of FBN1 variants may relate to learning or behavioral differences, but the size is too small to know how common this is. The database analysis is general and highlights that gene results and medication information do not always line up cleanly across reference sources, so this area remains uncertain and still developing. [16] [17] [18]